Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 35 of 116

  1. BAY2757556 (Larotrectinib, Vitrakvi)

    Bayer HealthCare AG

    Solid Tumors Harboring NTRK Fusion

    phase 2 small molecule completed

    1 trial

  2. BB-1701-G000-205

    Eisai Co.,

    HER2 positive or HER2-low metastatic breast cancer

    phase 2 other active

    1 trial

  3. BB-401

    Benitec Biopharma

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  4. BBI-20201001

    Bolt Biotherapeutics

    Advanced HER2-Expressing Solid Tumors.

    phase 2 small molecule active

    1 trial

  5. BC1 cell line

    BriaCell Therapeutics

    Breast Cancer

    phase 2 mab active

    1 trial

  6. BCG (50mg/instillation) + N-803 (400 μg/instillation)

    Immunitybio Ireland Limited

    Non-muscle Invasive Bladder Cancer

    phase 2 mab active

    1 trial

  7. BCMA CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma, Plasma Cell Leukemia

    phase 2 mab active

    1 trial

  8. BCX-1777

    Biocryst

    Leukemia, Lymphocytic

    phase 2 small molecule completed

    1 trial

  9. BCX1777-Tio-05-202

    Biocryst

    Leukemia

    phase 2 small molecule terminated

    1 trial

  10. BDB001

    Eikon Therapeutics

    Tumor, Solid

    phase 2 small molecule completed

    1 trial

  11. BDC-1001

    Bolt Biotherapeutics

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  12. BDC-1001

    Bolt Biotherapeutics

    HER2-positive Solid Tumors

    phase 2 small molecule terminated

    1 trial

  13. BDC-1001, PERTUZUMAB

    Bolt Biotherapeutics

    HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER

    phase 2 small molecule active

    1 trial

  14. BDC-4182

    Bolt Biotherapeutics

    Gastric Cancer Adenocarcinoma Metastatic

    phase 2 small molecule active

    1 trial

  15. BDH-CLL-002-2022/02/14

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  16. BEAM-201

    Beam Therapeutics

    Lymphoblastic Lymphoma

    phase 2 mab active

    1 trial

  17. BEVACIZUMAB, ATEZOLIZUMAB

    Pari Pharma GmbH

    liver transplanted patients with advanced hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  18. BFH-NCRTPD

    BEONE MEDICINES AUS PTY LTD

    Colorectal Neoplasms

    phase 2 other active

    1 trial

  19. BGB-10188

    BEONE MEDICINES AUS PTY LTD

    Chronic Lymphocytic Leukemia

    phase 2 small molecule completed

    1 trial

  20. BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  21. BGB-11417

    BEONE MEDICINES AUS PTY LTD

    Leukemia

    phase 2 small molecule active

    1 trial

  22. BGB-11417-103

    BEONE MEDICINES AUS PTY LTD

    Myeloid malignancies (acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN.

    phase 2 small molecule active

    1 trial

  23. BGB-11417-108

    BEONE MEDICINES AUS PTY LTD

    previously untreated chronic lymphocytic leukemia (CLL)

    phase 2 small molecule active

    1 trial

  24. BGB-11417-204

    BEONE MEDICINES AUS PTY LTD

    Previously Untreated Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  25. BGB-A317

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule completed

    1 trial

  26. BGB-A445

    BEONE MEDICINES AUS PTY LTD

    Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  27. BGJ398 (infigratinib)

    BridgeBio Oncology Therapeutics

    Advanced Cholangiocarcinoma

    phase 2 small molecule terminated

    1 trial

  28. BI-754091 plus afatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule completed

    1 trial

  29. BL-B01D1

    Sichuan Baili Pharmaceutical Co.,

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  30. BL-B01D1

    Sichuan Baili Pharmaceutical Co.,

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  31. BL0020

    Shanghai Best-Link Bioscience

    Small Cell Carcinoma of Lung

    phase 2 small molecule active

    1 trial

  32. BLEOMYCIN

    Fondazione Telethon ETS

    colorectal cancer

    phase 2 small molecule active

    1 trial

  33. BLEOMYCIN, CISPLATIN

    Fondazione Telethon ETS

    patients with newly diagnosed or recurrent high-grade or initially invasive precancerous squamous lesions of the vulva and non-invasive vulvar Paget's disease

    phase 2 small molecule active

    1 trial

  34. BLEOPRIM for CARCINOMA OF THE ORAL CAVITY AN…

    Fondazione Telethon ETS

    CARCINOMA OF THE ORAL CAVITY AND OROPHARYNX

    phase 2 small molecule active

    1 trial

  35. BLEOPRIM for Locally Advanced Pancreatic Can…

    Fondazione Telethon ETS

    Locally Advanced Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  36. BLU-285-3101

    Blueprint Medicines (Netherlands) B.V.

    Solid Tumors Dependent on KIT or PDGFRA Signaling

    phase 2 small molecule active

    1 trial

  37. BMS-986466

    Bristol-Myers Squibb

    Advanced Solid Tumors

    phase 2 small molecule terminated

    1 trial

  38. BMS-986504

    Bristol-Myers Squibb

    Solid Tumors

    phase 2 small molecule active

    1 trial

  39. BMS-986517

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  40. BMS-986523, BMS-986523

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  41. BNT111

    Regeneron UK Limited

    Melanoma Stage III

    phase 2 mab completed

    1 trial

  42. BNT111-01

    BioNTech SE

    Melanoma (Stage III and IV)

    phase 2 small molecule active

    1 trial

  43. BNT116

    Regeneron UK Limited

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  44. BNT142

    BioNTech SE

    Solid Tumors

    phase 2 small molecule active

    1 trial

  45. BNT314-02

    BioNTech SE

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  46. BNT321-02

    BioNTech SE

    Resected (R0 or R1) pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  47. BNT326-01

    BioNTech SE

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  48. BNT326-02

    BioNTech SE

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.